EMD

9.09%

3.0¢

EMYRIA LIMITED

Market Cap $12.46M Add to my watchlist

Healthcare

Emyria Limited is an Australia-based early-stage drug development company. The Company is... Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises medication-assisted treatment programs and biopharmaceuticals, specifically methylenedioxy-methylamphetamine (MDMA) analogues and Ultra-Pure cannabidiol (CBD) capsules. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.More

NATURAL MEDICINE LEADERS

The Calmer Co’s MD & CEO, Anthony Noble, highlights the company’s impressive financial performance for FY24.

Latest Threads

Tag

Subject

EMD

general talk

5 6 7

04/11/24

373

136K

04/11/24

Last post FiSaver

373

136K

EMD

Ann: Proposed issue of securities - EMD

31/10/24

244

31/10/24

Last post

ASX News

244

EMD

Ann: Emyria & UWA Partner to License Novel Serotonin Therapies

31/10/24

390

31/10/24

Last post

ASX News

390

EMD

Ann: September 2024 Quarterly Activities Report and Appendix 4C

30/10/24

1.3K

30/10/24

Last post rasberry

1.3K

EMD

Ann: Emyria Gains Ethics Endorsement for Psilocybin Program

28/10/24

867

28/10/24

Last post rasberry

867

EMD

Ann: Annual Report

13/10/24

1.0K

13/10/24

Last post 6beersaday

1.0K

EMD

Ann: Letter to Shareholders - Notice of Annual General Meeting

11/10/24

200

11/10/24

Last post

ASX News

200

EMD

Ann: Notice of Annual General Meeting/Proxy Form

11/10/24

231

11/10/24

Last post

ASX News

231

See All Discussions

Timeline

Proposed issue of securities - EMD
31 Oct 10:44	Share

Emyria & UWA Partner to License Novel Serotonin Therapies
31 Oct 09:58	Share

September 2024 Quarterly Activities Report and Appendix 4C
30 Oct 10:38	Share

Emyria Gains Ethics Endorsement for Psilocybin Program
28 Oct 10:00	Share

Letter to Shareholders - Notice of Annual General Meeting
11 Oct 15:53	Share

Notice of Annual General Meeting/Proxy Form
11 Oct 15:52	Share

Appendix 4G and Corporate Governance Statement
11 Oct 15:50	Share

Annual Report
11 Oct 15:50	Share

Change of Director's Interest Notice x 2
23 Sep 12:38	Share

Section 708A(5)(e) Notice
20 Sep 17:26	Share

Notification regarding unquoted securities - EMD
20 Sep 17:19	Share

Application for quotation of securities - EMD
20 Sep 17:15	Share

2024 Annual General Meeting - Key Dates
16 Sep 17:27	Share

Hidden Gems Webinar Presentation
06 Sep 08:58	Share

Emyria Shares Interim Success in PTSD Treatment Program
02 Sep 09:50	Share

Appendix 4E & Annual Report for the Year Ended 30 June 2024
30 Aug 14:35	Share

Results of Meeting
21 Aug 16:43	Share

June 2024 Quarterly Activities Report and Appendix 4C
30 Jul 09:06	Share

Letter to Shareholders - Notice of General Meeting
19 Jul 11:08	Share

Notice of General Meeting/Proxy Form
19 Jul 11:08	Share

Becoming a substantial holder
15 Jul 19:14	Share

Ceasing to be a substantial holder
15 Jul 19:12	Share

Emyria, UWA Secure $499K Grant for MDMA Analogue Program
01 Jul 09:30	Share

Empax Centre Selected As Key Site In Global PTSD Study
20 Jun 08:21	Share

Management Changes
11 Jun 08:22	Share

Change in substantial holding
10 May 08:17	Share

Section 708A(5)(e) Notice
07 May 18:42	Share

Notification regarding unquoted securities - EMD
07 May 18:39	Share

Application for quotation of securities - EMD
07 May 18:37	Share

March 2024 Quarterly Activities Report and Appendix 4C
26 Apr 08:40	Share

View More

(20min delay)
Last 3.0¢		Change -0.003(9.09%)		Mkt cap ! $12.46M

Open	High	Low	Value	Volume
3.1¢	3.1¢	3.0¢	$8.437K	272.3K

Buyers (Bids)

No.	Vol.	Price($)
8	448106	3.0¢

Sellers (Offers)

Price($)	Vol.	No.
3.3¢	65063	2

View Market Depth

No.	Vol.	Price($)
8	448106	0.030
4	110414	0.029
3	41500	0.028
1	111111	0.027
1	336336	0.026

Price($)	Vol.	No.
0.033	65063	2
0.034	193645	1
0.036	72967	1
0.037	31300	1
0.038	26315	1

Last trade - 11.44am 07/11/2024 (20 minute delay)


Last 3.1¢		Change -0.003 ( 0.00 %)
Open	High	Low	Volume
3.1¢	3.1¢	3.1¢	30891
Last updated 11.22am 07/11/2024 ?

EMD (ASX) Chart

EMYRIA LIMITED

Latest Threads

Red Mountain Mining (ASX:RMX) announces Bonanza Grade Gold Results at Flicka Lake

Timeline

Featured News

Latest Videos

Emyria (ASX:EMD) recruits first patient in MDMA-assisted therapy trial for PTSD

10 Jul 2023 12:47 (AEST)

Emyria (ASX:EMD) pockets more than $2m R&D tax refund

12 Jan 2023 10:34 (AEDT)

Latest Articles

Emyria, UWA seek commercialisation of compounds to treat PTSD and Parkinson's

Emyria and the University of Western Australia have formed a partnership to secure global rights to a library of patented compounds.

Emyria jumps 10% on 'interim' success treating PTSD patients with MDMA

Shares in MDMA psychotherapy player Emyria (ASX:EMD) jumped 9.4% to 3.5cps on Monday following reports of 'interim' success treating patients with PTSD.

Emyria and UWA secure $499,411 grant to advance MDMA analogue drug program

Emyria Ltd has been awarded a grant of $499,411 to advance its MDMA analogue drug development program to treat a range of conditions.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News